(Society of Nuclear Medicine and Molecular Imaging) German researchers have developed a novel diagnostic and therapeutic (theranostic) procedure for patients with ductal pancreatic adenocarcinoma, a deadly cancer with an extremely poor prognosis (five-year survival rate of less than 5 percent) and limited treatment options. The study is featured in the May issue of The Journal of Nuclear Medicine.

Related Links:

In this study, we investigated the antitumor and anti-metastasis efficacy of the selective FGFR1 inhibitor, PD173074 in PDAC. We used immunohistochemical and in situ hybridization analyses to demonstrate a strong correlation between FGFR1 amplification and/or expression and disease progression in PDAC patients. We showed that ALDHhigh (ALDH+) pancreatic cancer cells exhibited stem cell-like phenotype and expressed higher levels of FGFR1, Src, NF- κB, alongside stemness markers like Oct4 and Sox2, compared to their ALDHlow/null (ALDH −) counterparts, suggesting the preferential activation of the FGFR1/Src/NF-&ka…

Platinum-based therapy may improve survival in pancreatic ductal adenocarcinoma carrying deleterious germline mutations.JCO Precision Oncology

Source: Medscape Today HeadlinesCategory: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Publication date: Available online 28 June 2018Source: Advances in Biological RegulationAuthor(s): Stephen L. Abrams, Kvin Lertpiriyapong, Li V. Yang, Alberto M. Martelli, Lucio Cocco, Stefano Ratti, Marco Falasca, Ramiro M. Murata, Pedro L. Rosalen, Paolo Lombardi, Massimo Libra, Saverio Candido, Giuseppe Montalto, Melchiorre Cervello, Linda S. Steelman, James A. McCubreyAbstractPancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10%. Mutations at the TP53 gene are read…

Publication date: May 2018Source: Advances in Biological Regulation, Volume 68Author(s): Saverio Candido, Stephen L. Abrams, Linda Steelman, Kvin Lertpiriyapong, Alberto M. Martelli, Lucio Cocco, Stefano Ratti, Matilde Y. Follo, Ramiro M. Murata, Pedro L. Rosalen, Paolo Lombardi, Giuseppe Montalto, Melchiorre Cervello, Agnieszka Gizak, Dariusz Rakus, Pann-Gill Suh, Massimo Libra, James A. McCubreyAbstractPancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10% after diagn…

Publication date: May 2018Source: Advances in Biological Regulation, Volume 68Author(s): Aleksandra Adamska, Omar Elaskalani, Aikaterini Emmanouilidi, Minkyoung Kim, Norbaini Binti Abdol Razak, Pat Metharom, Marco FalascaAbstractPancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation of alternative compensatory pathways. Most of the available treatments are palliative, focussing on improving the quality of life. At present, available options are surgery, em…

ConclusionCombination of systemic chemotherapy and oligometastasectomy with adjunctive local IRE therapy is a feasible treatment strategy in highly select patients with oligometastatic PDAC that demonstrate favorable tumor biology with objective response to systemic therapy.

ConclusionsThere have been significant improvements in pancreatic cancer care over the last decade, as evidenced by earlier diagnosis, increased utilization of surgery, and improvement in overall survival for both resected and un-resected patients.

ConclusionSecond-opinion review by subspecialized oncologic radiologists can impact patient care, specifically in terms of management decision.

ConclusionsMajor cell-cycle regulator also have predictive significance, but further studies are required to evaluate this.

Publication date: June 2018Source: Pathology – Research and Practice, Volume 214, Issue 6Author(s): Deborah Saraggi, Francesca Galuppini, Giuseppe N. Fanelli, Andrea Remo, Emanuele D.L. Urso, Ricardo Q. Bao, Deborah Bacchin, Vincenza Guzzardo, Claudio Luchini, Chiara Braconi, Fabio Farinati, Massimo Rugge, Matteo FassanAbstractPoor information is available on the molecular landscape characterizing the carcinogenetic process leading to ampullary carcinoma. MiR-21 is one of the most frequently up-regulated miRNAs in pancreatic adenocarcinoma, a tumor sharing similar molecular features with ampullary adenocarcinomas (AVCs), a…





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image